$80,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to oncology, Medicare coverage, domestic production of essential drugs, supply chain security, PILLS Act, Biosecure Act, Loans and grants for biologic production Issues related to drug development, oncology, IRA implementation, supply chain security, BIOSECURE as a policy matter, PILLS Act, and domestic production of essential drugs. Strategic National Stockpile of acute radiation syndrome medical counter measures. Administration for Strategic Preparedness & Response."
You can find more data on corporate lobbying on Quiver Quantitative.
CHRS Hedge Fund Activity
We have seen 60 institutional investors add shares of CHRS stock to their portfolio, and 59 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TANG CAPITAL MANAGEMENT LLC removed 2,372,853 shares (-46.6%) from their portfolio in Q4 2025, for an estimated $3,369,451
- MACQUARIE GROUP LTD removed 899,999 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $1,277,998
- RUBRIC CAPITAL MANAGEMENT LP removed 867,800 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,423,192
- TEJARA CAPITAL LTD removed 698,770 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,145,982
- MILLENNIUM MANAGEMENT LLC added 660,451 shares (+inf%) to their portfolio in Q4 2025, for an estimated $937,840
- GSA CAPITAL PARTNERS LLP added 477,481 shares (+inf%) to their portfolio in Q4 2025, for an estimated $678,023
- TWO SIGMA INVESTMENTS, LP added 468,163 shares (+1310.9%) to their portfolio in Q4 2025, for an estimated $664,791
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
